

- Pancreatic cancer (*Cont.*):
 obstruction due to, 1892, 1894f
 paraneoplastic syndromes in, 609t, 612t, 619
 precursor lesions in, 554
 prognosis of, 556f
 risk factors for, 554
 screening for, 554
 staging of, 555, 556f
 treatment of, 102e-5t, 555, 556t, 557, 557t
 tumor markers in, 473t, 555
- Pancreatic cholera. *See* VIPoma (vasoactive intestinal peptidoma)
- Pancreatic disease. *See also* Pancreatitis
 abdominal pain in, 103-104
 annular pancreas, 2102
 approach to the patient, **2086**
 ascites in, 288
 back pain in, 118
 cancer. *See* Pancreatic cancer
 in cystic fibrosis, 1697. *See also* Cystic fibrosis (CF)
 diagnosis of
 biopsy, 2089
 imaging, 2087t, 2088-2089, 2089t
 pancreatic enzymes, 2087-2088, 2087t
 pancreatic function tests, 2087t, 2090
 endocrine tumors. *See* Pancreatic neuroendocrine tumors (pNETs)
 etiology of, 2086
 macroamylasemia, 2102
 pancreas divisum, 2102
 skin manifestations of, 366
- Pancreatic enzyme(s)
 activation of, in pancreatitis, 2090
 for irritable bowel syndrome, 1969
 in pancreatic disease diagnosis, 2087-2088, 2087t, 2089t
- Pancreatic enzyme preparations, 272, 2100-2101, 2101t
- Pancreatic intraepithelial neoplasia (PanIN), 554
- Pancreatic necrosis, 346e-1v, 1881, 2095-2096
- Pancreatic neuroendocrine tumors (pNETs), **567**
 classification of, 558, 559t, 560
 clinical features of, 559t, 567
 Cushing's syndrome and, 559t, 571
 general characteristics of, 558t
 genetic syndromes associated with, 562, 562t
 incidence of, 559t, 560-561, 561t
 malignant behavior of, 559t, 561-562
 nonfunctional, **571**, 2338, 2338f
 paraneoplastic syndromes in, 609t
 prognosis of, 561t, 573f
 rare syndromes, 559t, 571
 screening tests for, 2337t
 syndromes of, 559t
 glucagonoma. *See* Glucagonoma
 GRFoma, 559t, **571**
 insulinoma. *See* Insulinoma
 in MEN 1, 2336, 2336t
 somatostatinoma, 269, 559t, 561, **570**
 VIPoma. *See* VIPoma (vasoactive intestinal peptidoma)
 Zollinger-Ellison syndrome. *See* Zollinger-Ellison syndrome (ZES)
 treatment of, 102e-3, 103e-16, 568, 572-573
 tumor localization in, 571-572, 572f
- Pancreaticoduodenectomy, 553, 555
- Pancreaticopleural fistula, 2095f
- Pancreatic polypeptide (PP), 571
- Pancreatic polypeptide-secreting tumors (PPomas), 559t, 2338
- Pancreatitis. *See also* Acute pancreatitis; Chronic pancreatitis
 ascites in, 287
 autoimmune, 391e-1, 391e-1t, 2099, 2099t
 choledocholithiasis and, 2084
 cobalamin malabsorption in, 645
 diagnosis of, 107
 differential diagnosis of, 2093
 endoscopic findings in, 1899-1900
 gallstone, 1893-1894, 2096
 hereditary, 554, 2101
 hypocalcemia in, 315
 hypovolemia in, 298
 in mumps, 231e-3
 nausea and vomiting in, 259
 pleural effusions in, 2092, 2095f
 post-ERCP, 1891
 tumor markers in, 473t
- Pancuronium, 1784
- Pancytopenia, 662, 663t
- Panencephalitis, 900
- Paneth cells, 86e-8
- Pan-genome, 86e-1t, 86e-2
- Panic attack, 254
- Panic disorder, 96t, 101, **2708**
- PanIN (pancreatic intraepithelial neoplasia), 554
- Panitumumab
 action and targets of, 102e-5t
 adverse effects of, 103e-26, 543
 for colorectal cancer, 102e-5t, 543
 genetic variations in response to, 39t, 41
- Panniculitis, 364t, 366
- PanOptic ophthalmoscopy, 40e-2, 40e-2t
- Panton-Valentine leukocidin (PVL) toxin, 807, 830, 956
- Pantoprazole, 263, 1920, 1920t, 1930
- Pantothenate kinase-associated neurodegeneration (PKAN), 2611, 2626
- Pantothenic acid (vitamin B₅), 95e-2t, **96e-5**, 98e-5t
- Panuveitis, 200
- PAP (pulmonary alveolar proteinosis), 1714
- Papain, 2739, 2740
- PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome, 372e-8t, 422
- Papillary fibroelastoma, 289e-2
- Papillary necrosis, 1860, 1860t
- Papillary renal carcinoma, 101e-5, 101e-6t, 578, 578t. *See also* Renal cell carcinoma (RCC)
- Papillary stenosis, 2082
- Papilledema, 40e-5, 40e-5f, 203, 203f
- Papillomaviruses. *See* Human papillomavirus (HPV)
- Papillon-Lefevre syndrome, 236
- PA/PRA. *See* Aldosterone-renin-ratio (ARR)
- Pap smear, 28t, 29t, 480, 481t, 595
- Papular eruptive xanthomas, 436e-4f
- Papular mucinosis, 364t, 365
- Papule, 127, 339t, 340f. *See also* Papulonodular skin lesions
- Papulonodular skin lesions, **363**
 blue, 364t, 367
 etiology of, 828t, 829
 pink, 364t, 365
 purple, 364t, 367
 red, 364t, 365-367
 red-brown, 364t, 367
 skin-colored, 364-365, 364t
 violaceous, 364t, 367
 white, 363-364, 364t
 yellow, 364t, 365
- Papulosis, lymphomatoid, 710
- Papulosquamous lesions, **353**, 353t
- PAR1 (protease activation receptor 1), 276, 742
- Para-aminosalicylic acid, 205e-6-7, 644t
- Parabacteroides distasonis*, 1094
- Paracellular transport, 332e-3
- Paracentesis, abdominal, 287, 288, 474, 483e-1v
- Parachlorophenylamine, 567
- Paracoccidioidomycosis, 1354, 1354t
- Paracrine regulation, 400e-6
- Paradoxical pulse, 1574
- Paradoxical undressing, 478e-1
- Paraesophageal hernia, 1902
- Parafacial respiratory group, 1720
- Parafibromin, 2337t, 2342
- Paraganglioma
 definition of, 2329
 diagnosis of, 2329-2330, 2330t
 genetic considerations in, 1619, 2329, 2334-2335, 2334f
 hypertension in, 1619
 pathogenesis of, 2329, 2330f
 treatment of, 2330-2331
- Paraganglioma syndromes, 2332, 2333f
- Paragonimus* spp. *See* Lung flukes (*Paragonimus* spp.)
- Parainfluenza virus, 1207
- Parainfluenza virus infections, **1207**
 in cancer patient, 489, 1207
 clinical features of, 225, 226, 231, 234, 1202t, 1207
 diagnosis of, 1207
 epidemiology of, 1207
 pathogenesis of, 1207
 prevention of, 1208
 in transplant recipient, 923, 1207
 treatment of, 214e-5, 1207-1208
- Paralysis
 definition of, 154
 periodic. *See* Periodic paralysis
 in rabies, 1301-1302
 sleep, 188t, 189
 tick-bite, 989, 2745
 Todd's, 2542
 tongue, 2649
- Paralytic poliomyelitis, 1290. *See also* Poliovirus infection
- Paralytic shellfish poisoning, 2742
- Paramyotonia congenita, 444e-2t, 462e-3, 462e-17t, 462e-18
- Paramyxoviruses
 gene expression and replication in, 214e-4
 human metapneumovirus, 1206
 measles. *See* Measles (rubeola)
 mumps. *See* Mumps
 structure of, 214e-2t
- Paranasal sinus cancer. *See* Head and neck cancer
- Paraneoplastic syndromes
 ataxia in, 2626
 definition of, 608
 endocrinologic, **608**
 ectopic ATCH production. *See* Adrenocorticotropic hormone (ACTH), ectopic production of
 ectopic hCG production, 608, 612
 etiology of, 608-609, 609t
 hypercalcemia. *See* Hypercalcemia, malignancy-associated
 oncogenic osteomalacia, 612
 tumor-associated SIADH, 610. *See also* Syndrome of inappropriate antidiuretic hormone (SIADH)
 tumor-induced hypoglycemia, 611-612
 eye movements in, 41e-1v
 hematologic, **612**, 612t
 in hepatocellular carcinoma, 545-546
 immunopathology of, 372e-25t
 joint involvement in, 2247
 in lung cancer, 511
 neurologic, **614**, 614t
 acute necrotizing myopathy, 619
 anti-Hu neuropathy, 2700
 approach to the patient, 615-616
 autoimmune autonomic ganglionopathy, 2642
 cerebellar degeneration/atrophy, 372e-25t, 614t, 617-618
 channelopathies in, 444e-2t
 vs. Creutzfeldt-Jakob disease, 453e-5
 diagnosis of, 615-616, 615f
 dorsal root ganglionopathy, 618
 encephalitis with antibodies to cell-surface or synaptic proteins, 614t, 617, 617f, 2607
 encephalomyelitis and focal encephalitis, 372e-25t, 616-617, 616f
 Lambert-Eaton myasthenic syndrome. *See* Lambert-Eaton myasthenic syndrome (LEMS)
 opsoclonus-myoclonus syndrome, 372e-25t, 614t, 618
 pathogenesis of, 614, 614t
 peripheral neuropathies, 618-619
 sensory neuronopathy/ganglionopathy, 618, 2685
 spinal cord, 618